Sitaatteja

Hankkeessa mukana olevat yritykset ovat innostuneita tutkimuksen potentiaalista. Alla muutamia lausuntoja hankkeen merkityksestä heidän yrityksilleen.

Morten Søgaard

Executive Director, Head, Biotechnology & Precision Medicine, External R&D Innovation, Pfizer

“Pfizer is excited about the potential of the FinnGen consortium to provide a more holistic understanding of the genetic basis for onset and progression of human disease, and response to therapeutic intervention” said Morten Sogaard, Vice President and Head of Genome Sciences and technology, Worldwide Research and Development at Pfizer. “A large, genotype-to-phenotype resource, like FinnGen, is linked to world class electronic health records and laboratory data, which provides researchers with a high-quality resource to examine genetic variation in a population highly suitable to genetic studies. We hope that FinnGen will ultimately influence the discovery of new therapies that can help improve patient’s lives.”

 

Quote from Cecilia Young, Celgene

Nordic Medical Director at Celgene Nordic

"FinnGen is a unique data source of genetic information and health data. This constitutes a very valuable resource to identify novel targets for drug development, to validate known targets with causal human biology from 500,000 European individuals, as well as to perform robust safety and efficacy predictions and to conduct recall/epi studies. Additional partnerships will for sure emerge from this project, and this data source, including follow-up information, has the potential to become one of the very best in the world."

 

Eric Brown ja Thomas Zioncheck, Genentech

Eric Brown, Vice President of Immunology and Infectious Diseases, Genentech

"This study will provide us with valuable insights into pathways that drive disease, and will lead to the identification of new drug targets and biomarkers that advance our personalized medicine efforts for patients.” By Eric Brown, M.D., Vice President of Immunology and Infectious Diseases, Genentech

 

Thomas Zioncheck, Ph.D., Global Head of Neuroscience, Ophthalmology and Research Tools & Technologies, Genentech Business Development

"By harnessing genomic data and medical case histories from this unique population, we hope to gain a deeper understanding of genetic drivers of disease and potentially change how serious diseases are treated." By Thomas Zioncheck, Ph.D., Global Head of Neuroscience, Ophthalmology and Research Tools & Technologies, Genentech Business Development

 

Michael Casia, MSD

Managing Director, MSD Finland Oy

“Finland has established a strong research infrastructure to access potentially important genetic insights from its unique population heritage,” said Managing Director Michael Casia of MSD Finland Oy. “We look forward to applying our medicine and vaccine discovery expertise towards this collaboration.”

 

Steve Elmore, AbbVie

Ph.D., Vice President, Technology Discovery Research

“Genomics is transforming our understanding of human disease. This large-scale collaborative research project is uniquely positioned to help scientists harness the promise of human genetics research to develop improved therapies for patients.”